-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230

Benzinga·09/09/2026 15:01:10
语音播报
Stifel analyst Laura Prendergast maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $215 to $230.